Acute pain management pharmacology for the patient with concurrent renal or hepatic disease
- PMID: 15973913
- DOI: 10.1177/0310057X0503300306
Acute pain management pharmacology for the patient with concurrent renal or hepatic disease
Abstract
The clinical utility of most analgesic drugs is altered in the presence of patients with impaired renal or hepatic function not simply because of altered clearance of the parent drug, but also through production and accumulation of toxic or therapeutically active metabolites. Some analgesic agents may also aggravate pre-existing renal and hepatic disease. A search was performed, taking in published articles and pharmaceutical data to determine available evidence for managing acute pain effectively and safely in these two patient groups. The resulting information consisted mainly of small group pharmacokinetic studies or case reports, which included a large variation in degree of organ dysfunction. In the presence of renal impairment, those drugs which exhibit the safest pharmacological profile are alfentanil, buprenorphine, fentanyl, ketamine, paracetamol (except with compound analgesics), remifentanil and sufentanil. none of these deliver a high active metabolite load, or suffer from significantly prolonged clearance. Amitriptyline, bupivacaine, clonidine, gabapentin, hydromorphone, levobupivacaine, lignocaine, methadone, mexiletine, morphine, oxycodone and tramadol have been used in the presence of renal failure, but do require specific precautions, usually dose reduction. Aspirin, dextropropoxyphene, non-steroidal anti-inflammatory drugs and pethidine, should not be used in the presence of chronic renal failure due to the risk of significant toxicity. In the presence of hepatic impairment, most drugs are subject to significantly impaired clearance and increased oral bioavailability, but are poorly studied in the clinical setting. The agent least subject to alteration in this context is remifentanil; however the drugs' potency has other inherent dangers. Other agents must only be used with caution and close patient monitoring. Amitriptyline, carbamazepine and valproate should be avoided as the risk of fulminant hepatic failure is higher in this population, and methadone is contraindicated in the presence of severe liver disease.
Similar articles
-
Analgesics in patients with hepatic impairment: pharmacology and clinical implications.Drugs. 2012 Aug 20;72(12):1645-69. doi: 10.2165/11635500-000000000-00000. Drugs. 2012. PMID: 22867045
-
Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).Pain Pract. 2008 Jul-Aug;8(4):287-313. doi: 10.1111/j.1533-2500.2008.00204.x. Epub 2008 May 23. Pain Pract. 2008. PMID: 18503626
-
The use of major analgesics in patients with renal dysfunction.Curr Drug Targets. 2010 Jun;11(6):752-8. doi: 10.2174/138945010791170879. Curr Drug Targets. 2010. PMID: 20041843 Review.
-
Pharmacokinetics of opioids in liver disease.Clin Pharmacokinet. 1999 Jul;37(1):17-40. doi: 10.2165/00003088-199937010-00002. Clin Pharmacokinet. 1999. PMID: 10451781 Review.
-
[Opioids for Cancer Pain and its Use under Particular Conditions: A Narrative Review].Acta Med Port. 2019 May 31;32(5):388-399. doi: 10.20344/amp.10500. Epub 2019 May 31. Acta Med Port. 2019. PMID: 31166900 Review. Portuguese.
Cited by
-
An open-label, 1-year extension study of the long-term safety and efficacy of once-daily OROS(R) hydromorphone in patients with chronic cancer pain.BMC Palliat Care. 2009 Sep 15;8:14. doi: 10.1186/1472-684X-8-14. BMC Palliat Care. 2009. PMID: 19754935 Free PMC article.
-
The toxic profile of tramadol combined with nicotine on the liver and testicles: evidence from endoplasmic reticulum stress.Mol Biol Rep. 2023 Dec;50(12):9887-9895. doi: 10.1007/s11033-023-08903-6. Epub 2023 Oct 21. Mol Biol Rep. 2023. PMID: 37864661
-
Acute postoperative pain management after living donor hepatectomy during the transition from an open to minimally invasive surgical approach.Saudi J Anaesth. 2025 Jan-Mar;19(1):14-20. doi: 10.4103/sja.sja_415_24. Epub 2025 Jan 1. Saudi J Anaesth. 2025. PMID: 39958280 Free PMC article.
-
Ketamine for pain management.Pain Rep. 2018 Aug 9;3(5):e674. doi: 10.1097/PR9.0000000000000674. eCollection 2018 Sep-Oct. Pain Rep. 2018. PMID: 30534625 Free PMC article.
-
(-)-Naringenin 4',7-dimethyl Ether Isolated from Nardostachys jatamansi Relieves Pain through Inhibition of Multiple Channels.Molecules. 2022 Mar 7;27(5):1735. doi: 10.3390/molecules27051735. Molecules. 2022. PMID: 35268839 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical